Clinical Trials: SEARCH[Study] TILT[Study:StudyFirstPostDate] AREA[SponsorSearch] EMD Serono
#
NCTID/Status
Study
Last Changed
1
NCT02155647
Active, not recruiting
Active, not recruiting
Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Conditions: Carcinoma, Merkel Cell
Intervention: Avelumab
Conditions: Carcinoma, Merkel Cell
Intervention: Avelumab
December 5, 2019
2
NCT02117050
Terminated
Terminated
RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate
Conditions: Multiple Sclerosis
Intervention: Rebif®
Conditions: Multiple Sclerosis
Intervention: Rebif®
November 28, 2016
3
NCT02083679
Terminated
Terminated
Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer
Conditions: Carcinoma, Non-Small-Cell Lung
Conditions: Carcinoma, Non-Small-Cell Lung
August 29, 2016
4
NCT02070978
Terminated
Terminated
Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)
Conditions: Lupus Erythematosus, Systemic
Intervention: Atacicept 75 Mg, Atacicept 150 Mg, Atacicept 150 Mg
Conditions: Lupus Erythematosus, Systemic
Intervention: Atacicept 75 Mg, Atacicept 150 Mg, Atacicept 150 Mg
March 19, 2019
5
NCT02049151
Terminated
Terminated
Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
Conditions: Carcinoma, Non-Small-Cell Lung
Intervention: Tecemotide, Placebo, Cyclophosphamide (CPA), Saline (sodium Chloride)
Conditions: Carcinoma, Non-Small-Cell Lung
Intervention: Tecemotide, Placebo, Cyclophosphamide (CPA), Saline (sodium Chloride)
July 24, 2017
6
NCT02019550
Completed
Completed
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
Conditions: Multiple Sclerosis, Relapsing-Remitting
Conditions: Multiple Sclerosis, Relapsing-Remitting
January 13, 2017
7
NCT01992874
Completed
Completed
Relative Bioavailability of Pimasertib in Cancer Patients
Conditions: Neoplasms
Conditions: Neoplasms
July 6, 2017
8
NCT01973608
Terminated
Terminated
MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma
Conditions: Melanoma
Intervention: MSB0010445 (0.3 Milligram Per Kilogram [mg/kg]), MSB0010445 (1.0 Mg/kg), MSB0010445 (1.8 Mg/kg), MSB0010445 (2.4 Mg/kg), Stereotactic Body Radiation Therapy (SBRT)
Conditions: Melanoma
Intervention: MSB0010445 (0.3 Milligram Per Kilogram [mg/kg]), MSB0010445 (1.0 Mg/kg), MSB0010445 (1.8 Mg/kg), MSB0010445 (2.4 Mg/kg), Stereotactic Body Radiation Therapy (SBRT)
September 14, 2016
9
NCT01972568
Completed
Completed
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
Conditions: Lupus Erythematosus, Systemic
Intervention: Atacicept 75 Milligram (mg), Atacicept 150 Mg, Placebo
Conditions: Lupus Erythematosus, Systemic
Intervention: Atacicept 75 Milligram (mg), Atacicept 150 Mg, Placebo
December 4, 2017
10
NCT01971515
Completed
Completed
First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies
Conditions: Solid Tumor
Intervention: MSC2363318A, MSC2363318A Plus Trastuzumab, MSC2363318A Plus Tamoxifen
Conditions: Solid Tumor
Intervention: MSC2363318A, MSC2363318A Plus Trastuzumab, MSC2363318A Plus Tamoxifen
September 18, 2018
11
NCT01963611
Terminated
Terminated
Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)
Conditions: Relapsing Remitting Multiple Sclerosis
Intervention: Plovamer Acetate 0.5 Milligram (mg), Copaxone 20 Mg, Plovamer Acetate 3 Mg, Plovamer Acetate 10 Mg, Plovamer Acetate 20 Mg
Conditions: Relapsing Remitting Multiple Sclerosis
Intervention: Plovamer Acetate 0.5 Milligram (mg), Copaxone 20 Mg, Plovamer Acetate 3 Mg, Plovamer Acetate 10 Mg, Plovamer Acetate 20 Mg
April 5, 2016
12
NCT01936363
Completed
Completed
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
Conditions: Ovarian Cancer
Intervention: Pimasertib Once Daily, Pimasertib Placebo, SAR245409 Placebo, SAR245409, Pimasertib Twice Daily
Conditions: Ovarian Cancer
Intervention: Pimasertib Once Daily, Pimasertib Placebo, SAR245409 Placebo, SAR245409, Pimasertib Twice Daily
November 26, 2018
13
NCT01919164
Completed
Completed
A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the Knee
Conditions: Osteoarthritis, Knee
Intervention: Sprifermin 100 Microgram (mcg), Sprifermin 100 Microgram (mcg), Sprifermin 30 Microgram (mcg), Sprifermin 30 Microgram (mcg), Placebo, Placebo
Conditions: Osteoarthritis, Knee
Intervention: Sprifermin 100 Microgram (mcg), Sprifermin 100 Microgram (mcg), Sprifermin 30 Microgram (mcg), Sprifermin 30 Microgram (mcg), Placebo, Placebo
November 14, 2019
14
NCT01905527
Terminated
Terminated
Adherence Trial With MS LifeLines ® Services
Conditions: Multiple Sclerosis; Relapsing-Remitting
Intervention: Standard Services Of Group A (Group A1), Customized Services Of Group A (Group A2), Group B
Conditions: Multiple Sclerosis; Relapsing-Remitting
Intervention: Standard Services Of Group A (Group A1), Customized Services Of Group A (Group A2), Group B
January 30, 2015
15
NCT01772004
Active, not recruiting
Active, not recruiting
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Conditions: Solid Tumors
Intervention: Avelumab
Conditions: Solid Tumors
Intervention: Avelumab
December 3, 2019
16
NCT01693068
Completed
Completed
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Conditions: N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Intervention: Pimasertib, Dacarbazine
Conditions: N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Intervention: Pimasertib, Dacarbazine
December 5, 2017
17
NCT01689337
Terminated
Terminated
A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee
Conditions: Cartilage Injury of Knee
Intervention: Sprifermin (AS902330), Sprifermin (AS902330), Placebo
Conditions: Cartilage Injury of Knee
Intervention: Sprifermin (AS902330), Sprifermin (AS902330), Placebo
January 12, 2017
18
NCT01496131
Completed
Completed
Tecemotide (L-BLP25) in Prostate Cancer
Conditions: Prostate Cancer
Intervention: Radiation Therapy, Goserelin, Cyclophosphamide, Tecemotide (L-BLP25)
Conditions: Prostate Cancer
Intervention: Radiation Therapy, Goserelin, Cyclophosphamide, Tecemotide (L-BLP25)
February 9, 2018
19
NCT01453387
Terminated
Terminated
March 27, 2017
20
NCT01440231
Withdrawn
Withdrawn
Atacicept Demonstrating Dose RESponSe
Conditions: Systemic Lupus Erythematosus
Intervention: Placebo, Atacicept, Atacicept, Atacicept, Atacicept
Conditions: Systemic Lupus Erythematosus
Intervention: Placebo, Atacicept, Atacicept, Atacicept, Atacicept
August 20, 2013
21
NCT01390818
Completed
Completed
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Conditions: Locally Advanced Solid Tumor; Metastatic Solid Tumor; Breast Cancer; Non Small Cell Lung Cancer; Melanoma; Colorectal Cancer
Intervention: MSC1936369B (pimasertib), SAR245409 (PI3K And MTOR Inhibitor), MSC1936369B (pimasertib), SAR245409 (PI3K And MTOR Inhibitor)
Conditions: Locally Advanced Solid Tumor; Metastatic Solid Tumor; Breast Cancer; Non Small Cell Lung Cancer; Melanoma; Colorectal Cancer
Intervention: MSC1936369B (pimasertib), SAR245409 (PI3K And MTOR Inhibitor), MSC1936369B (pimasertib), SAR245409 (PI3K And MTOR Inhibitor)
January 17, 2017
22
NCT01378377
Terminated
Terminated
Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus
Conditions: Advanced Solid Tumor
Intervention: Pimasertib, Pimasertib, Temsirolimus, Temsirolimus
Conditions: Advanced Solid Tumor
Intervention: Pimasertib, Pimasertib, Temsirolimus, Temsirolimus
October 25, 2017
23
NCT01369628
Terminated
Terminated
Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil
Conditions: Lupus Nephritis
Conditions: Lupus Nephritis
October 21, 2013
24
NCT01360840
Completed
Completed
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
Conditions: Prostate Cancer Metastatic
Intervention: EMD 525797, EMD 525797, Placebo, Standard Of Care (SoC)
Conditions: Prostate Cancer Metastatic
Intervention: EMD 525797, EMD 525797, Placebo, Standard Of Care (SoC)
November 9, 2015
25
NCT01237340
Terminated
Terminated
Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study
Conditions: Growth Hormone Deficiency (GHD)
Intervention: Saizen®
Conditions: Growth Hormone Deficiency (GHD)
Intervention: Saizen®
August 4, 2013
26
NCT01226745
Terminated
Terminated
Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Conditions: Multiple Sclerosis
Intervention: ONO-4641, ONO-4641, ONO-4641, ONO-4641, ONO-4641, ONO-4641
Conditions: Multiple Sclerosis
Intervention: ONO-4641, ONO-4641, ONO-4641, ONO-4641, ONO-4641, ONO-4641
June 2, 2016
27
NCT01207648
Completed
Completed
Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)
Conditions: Multiple Sclerosis
Intervention: Rebif®
Conditions: Multiple Sclerosis
Intervention: Rebif®
April 27, 2015
28
NCT01152866
Completed
Completed
An Open Label, Canadian Phase IIIb Study With Ovidrel in Ovulation Induction (OI) and Assisted Reproductive Technique (ART)
Conditions: Ovulation Induction; Infertility
Intervention: Choriogonadotropin Alpha (r-hCG)
Conditions: Ovulation Induction; Infertility
Intervention: Choriogonadotropin Alpha (r-hCG)
August 4, 2013
29
NCT01121991
Completed
Completed
A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies
Conditions: Infertility; Ovarian Stimulation
Conditions: Infertility; Ovarian Stimulation
August 2, 2013
30
NCT01110083
Terminated
Terminated
First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors
Conditions: Solid Tumors
Intervention: EMD 1204831
Conditions: Solid Tumors
Intervention: EMD 1204831
October 21, 2013
31
NCT01085331
Terminated
Terminated
MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)
Conditions: Metastatic Colorectal Cancer
Intervention: Pimasertib, Placebo, FOLFIRI
Conditions: Metastatic Colorectal Cancer
Intervention: Pimasertib, Placebo, FOLFIRI
August 24, 2016
32
NCT01085318
Completed
Completed
Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
Conditions: Multiple Sclerosis
Intervention: Rebif
Conditions: Multiple Sclerosis
Intervention: Rebif
January 25, 2018
33
NCT01080664
Terminated
Terminated
A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies
Conditions: Haematological Malignancies
Intervention: AS703569, AS703569
Conditions: Haematological Malignancies
Intervention: AS703569, AS703569
October 21, 2013
34
NCT01077960
Completed
Completed
Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Conditions: Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Intervention: Serostim
Conditions: Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Intervention: Serostim
August 4, 2013
35
NCT01040832
Completed
Completed
EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Conditions: Squamous Cell Carcinoma of the Head and Neck Cancer
Intervention: Cetuximab, EMD 1201081
Conditions: Squamous Cell Carcinoma of the Head and Neck Cancer
Intervention: Cetuximab, EMD 1201081
January 12, 2017
36
NCT01036165
Completed
Completed
A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study
Conditions: Multiple Sclerosis
Intervention: RebiSmart™
Conditions: Multiple Sclerosis
Intervention: RebiSmart™
August 2, 2013
37
NCT01034735
Completed
Completed
r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial
Conditions: Growth Failure; Growth Hormone Deficiency
Intervention: R-hGH Liquid (Saizen), R-hGH Liquid (Saizen), R-hGH Freeze-dried
Conditions: Growth Failure; Growth Hormone Deficiency
Intervention: R-hGH Liquid (Saizen), R-hGH Liquid (Saizen), R-hGH Freeze-dried
October 22, 2013
38
NCT01034579
Completed
Completed
The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial
Conditions: Relapsing Multiple Sclerosis
Intervention: Blood Sampling, Blood Sampling
Conditions: Relapsing Multiple Sclerosis
Intervention: Blood Sampling, Blood Sampling
January 27, 2014
39
NCT01016483
Completed
Completed
Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer
Conditions: Pancreatic Adenocarcinoma
Intervention: Pimasertib, Gemcitabine, Placebo
Conditions: Pancreatic Adenocarcinoma
Intervention: Pimasertib, Gemcitabine, Placebo
July 12, 2017
40
NCT01014936
Completed
Completed
First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
Conditions: Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
Intervention: MSC2156119J
Conditions: Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
Intervention: MSC2156119J
July 19, 2017
41
NCT01013350
Completed
Completed
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials
Conditions: Multiple Sclerosis
Conditions: Multiple Sclerosis
October 24, 2019
42
NCT00958009
Completed
Completed
The Multicenter, Open-label, Single-use Autoinjector Convenience Study
Conditions: Multiple Sclerosis
Intervention: Rebidose®
Conditions: Multiple Sclerosis
Intervention: Rebidose®
August 2, 2013
43
NCT00957580
Terminated
Terminated
Trial of Pimasertib in Hematological Malignancies
Conditions: Leukemia, Myeloid, Acute; Hematologic Neoplasms
Intervention: Pimasertib, Pimasertib, Pimasertib, Pimasertib, Pimasertib
Conditions: Leukemia, Myeloid, Acute; Hematologic Neoplasms
Intervention: Pimasertib, Pimasertib, Pimasertib, Pimasertib, Pimasertib
July 19, 2017
44
NCT00925548
Terminated
Terminated
STRIDE - STimulating Immune Response In aDvanced brEast Cancer
Conditions: Breast Cancer
Intervention: Tecemotide (L-BLP25) And Hormonal Treatment, Placebo Of Tecemotide (L-BLP25) And Hormonal Treatment, Cyclophosphamide, Sodium Chloride (NaCl)
Conditions: Breast Cancer
Intervention: Tecemotide (L-BLP25) And Hormonal Treatment, Placebo Of Tecemotide (L-BLP25) And Hormonal Treatment, Cyclophosphamide, Sodium Chloride (NaCl)
July 23, 2014
45
NCT00853762
Terminated
Terminated
Atacicept in Multiple Sclerosis Extension Study, Phase II
Conditions: Relapsing Multiple Sclerosis
Intervention: Atacicept 25 Mg, Atacicept 75 Mg, Atacicept 150 Mg, Atacicept 150 Mg
Conditions: Relapsing Multiple Sclerosis
Intervention: Atacicept 25 Mg, Atacicept 75 Mg, Atacicept 150 Mg, Atacicept 150 Mg
February 12, 2017
46
NCT00813943
Completed
Completed
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status
Conditions: Glioblastoma
Intervention: Cilengitide (2-times Weekly), Cilengitide (5-times Weekly), Temozolomide, Radiotherapy
Conditions: Glioblastoma
Intervention: Cilengitide (2-times Weekly), Cilengitide (5-times Weekly), Temozolomide, Radiotherapy
January 12, 2017
47
NCT00735007
Completed
Completed
12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.
Conditions: Multiple Sclerosis
Conditions: Multiple Sclerosis
October 21, 2013
48
NCT00725985
Completed
Completed
Oral Cladribine in Early Multiple Sclerosis (MS)
Conditions: Multiple Sclerosis
Intervention: Cladribine, Cladribine, Placebo, Rebif® New Formulation (RNF)
Conditions: Multiple Sclerosis
Intervention: Cladribine, Cladribine, Placebo, Rebif® New Formulation (RNF)
September 5, 2017
49
NCT00719199
Terminated
Terminated
Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer
Conditions: Colorectal Cancer
Intervention: IMO-2055, Cetuximab, FOLFIRI
Conditions: Colorectal Cancer
Intervention: IMO-2055, Cetuximab, FOLFIRI
October 21, 2013
50
NCT00702065
Completed
Completed
A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment
Conditions: Multiple Sclerosis
Conditions: Multiple Sclerosis
June 16, 2014
Last Updated
The last updated date is the most recent date when changes to a clinical trial were
submitted to ClinicalTrials.gov. There is often a delay of a few days before the
updated trial is available on the clinical trials website.
Specify a From date to find the most recently changed trials. Specify both From and To dates to find trials changed during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Specify a From date to find the most recently changed trials. Specify both From and To dates to find trials changed during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
First Received
The first received date is the date when the clinical trial was first submitted
to ClinicalTrials.gov. There is often a delay of a few days before the
trial is available on the clinical trials website.
Clinical trial records are often updated after they have been published. The first received, last updated, start, and end dates are all displayed in the full text view of the clinical trial.
Specify a From date to find the most recent trials. Specify both From and To dates to find trials submitted during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Clinical trial records are often updated after they have been published. The first received, last updated, start, and end dates are all displayed in the full text view of the clinical trial.
Specify a From date to find the most recent trials. Specify both From and To dates to find trials submitted during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Safety Issue
If selected, restricts search results to those studies which have
an outcome measure designated as a safety issue. Note that this is a
poor estimate of the safety of a treatment or intervention, but it is
all we have now.
Funded By
Studies are supported by one or more organizations called sponsors.
Support includes contributions of facilities, expertise, and/or financial resources.
All sponsors in the database have been assigned one of the following organization types:
National Institutes of Health (NIH)
Other U.S. Federal Agency - Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Veterans Affairs (VA), etc.
Industry - the pharmaceutical companies
University/Organization - all others, including community-based organizations
Click the check box to the left of each organization type that you wish to include in your search. You can select more than one organization type. If you do not select any type, all types will be included.
National Institutes of Health (NIH)
Other U.S. Federal Agency - Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Veterans Affairs (VA), etc.
Industry - the pharmaceutical companies
University/Organization - all others, including community-based organizations
Click the check box to the left of each organization type that you wish to include in your search. You can select more than one organization type. If you do not select any type, all types will be included.
Study Phase
Click the check box to the left of each study phase that you wish to include in your search. You can select more than one study phase. If you do not select a any phase, all phases will be included.
Most clinical trials are designated as phase 1, 2, 3, or 4, based on the type of questions
that study is seeking to answer:
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
Click the check box to the left of each study phase that you wish to include in your search. You can select more than one study phase. If you do not select a any phase, all phases will be included.
Age Group
Studies may be designed for participants of particular ages:
Children (birth-17 yrs old)
Adults (18-65 yrs old)
Senior (66+ yrs old)
Click the check box to the left of each age group that you wish to include in your search. You can select more than one age group. If you do not select a any group, all groups will be included.
Children (birth-17 yrs old)
Adults (18-65 yrs old)
Senior (66+ yrs old)
Click the check box to the left of each age group that you wish to include in your search. You can select more than one age group. If you do not select a any group, all groups will be included.
Gender
Searches can be restricted to studies which accept female or male participants.
Location Terms
If you are interested in a specific city (such as Los Angeles) or facility
name (such as the Mayo Clinic), enter it as a location term. Not all studies
include this level of detail, but if they do, this will find them.
Countries and States
Trials are often conducted at many locations around the world.
Select up to three locations to find trials conducted in
specific countries. Some countries (currently limited to the
United States, Canada, and Australia), locations can be narrowed
further by selecting a state.
Study IDs
Each trial is assigned one or more identification numbers by the institute, agency,
or organization sponsoring the trial. In addition, clinical trials assigns a
unique NCT identifier of the form NCTxxxxxxxx where each x is a numeric digit.
Use this box to search for a trial by NCT identifier or any other study
identification numbers.
Examples:
Examples:
NCT00001789
97-h-0197
ia0006
actg 076
97-h-0197
ia0006
actg 076
Sponsor (Lead)
Use this box to specify the name of an institute, organization, or company that is
conducting a trial.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
A search in this area will check only the sponsor field. To also look for collaborators, use the Sponsor/Collaborators search box.
When the Exact Match checkbox is checked, the sponsor name in the study must exactly match the sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
A search in this area will check only the sponsor field. To also look for collaborators, use the Sponsor/Collaborators search box.
When the Exact Match checkbox is checked, the sponsor name in the study must exactly match the sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
Sponsor/Collaborators
Use this box to specify institutes, organizations, or companies that are
conducting or otherwise supporting a trial.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
Searching this area will look in both the sponsor field and in the collaborators field. To only look in the sponsor field, use the Sponsor (Lead) search box.
When the Exact Match checkbox is checked, the name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
Searching this area will look in both the sponsor field and in the collaborators field. To only look in the sponsor field, use the Sponsor (Lead) search box.
When the Exact Match checkbox is checked, the name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
Outcome Measures
Use this box to specify an outcome measure used to evaluate trial results.
Examples:
weight loss
heart failure
suicide
Outcome measures are used to evaluate trial results. For example, an obesity treatment
might be evaluated by a measure of weight loss after 6 months. Measures can also be used
to quantify side effects, such as number of myocardial infarctions,
number of patients with heart arrhythmia, number of suicides, etc.
Use this box to specify an outcome measure used to evaluate trial results.
Examples:
weight loss
heart failure
suicide
Interventions
Use this box to specify drugs, devices, procedures, or vaccines used in a trial.
Examples:
clofibrate
cyclosporine
vitamin e
Interventions refer to the drug, vaccine, procedure, device, or other potential treatment being studied.
Interventions can also include less intrusive possibilities such as surveys, education, and interviews.
Use this box to specify drugs, devices, procedures, or vaccines used in a trial.
Examples:
clofibrate
cyclosporine
vitamin e
Conditions
Use this box to specify the conditions being studied.
Examples:
lupus
heart attack
leukemia
risk factors for breast cancer
Conditions usually refer to a disease, disorder, syndrome, illness, or injury. In ClinicalTrials.gov,
conditions include any health issue worth studying, such as lifespan, quality of life, health risks, etc.
Use this box to specify the conditions being studied.
Examples:
lupus
heart attack
leukemia
risk factors for breast cancer
Study Type
There are three types of studies available in ClinicalTrials.gov:
There are three types of studies available in ClinicalTrials.gov:
Interventional:
Observational:
Expanded Access:
Studies where individuals are assigned to receive specific interventions.
Participants may receive diagnostic, therapeutic or other types of interventions.
Assignment of the intervention may or may not be random.
Individuals are tracked and biomedical and/or health outcomes are assessed.
Observational:
Studies without an intervention.
Studies where biomedical and/or health outcomes are assessed in a pre-defined group of individuals.
Participants may receive diagnostic, therapeutic, or other interventions, but the investigator
does not assign specific interventions to the participants of the study.
Expanded Access:
Records describing the procedure for obtaining an experimental drug or device for patients who
are failing on currently available treatments for their condition and also are unable to
participate in ongoing clinical trials. Expanded Access records are used to register all
types of non-protocol access to experimental treatments, including protocol exception,
single-patient IND, treatment IND, compassionate use, emergency use, continued access and parallel track.
Study Results
Searches can be restricted to studies with or without results.
The inclusion of study results is a relatively new feature of ClinicalTrials.gov. Collection of results began in September of 2008. Almost all older studies and some newer studies do not include results. As time goes on, there will be more results available.
The inclusion of study results is a relatively new feature of ClinicalTrials.gov. Collection of results began in September of 2008. Almost all older studies and some newer studies do not include results. As time goes on, there will be more results available.
Recruitment Status
Also known as Enrollment Status.
Not all clinical trials in this database are accepting new participants. If you are looking for studies that are currently recruiting participants, will be recruiting in the future, or are about drugs that are available for expanded access, select Open Studies in the recruitment menu.
If you are interested in all trials, whether they are recruiting new participants or not, leave the menu with All Studies selected.
Trials may not be recruiting because they are full, completed, or halted for various reasons. In addition, some trials have very restrictive eligibility requirements and must seek participants by invitation only. To see these studies, Select Closed Studies in the recruitment menu.
Full list of all possible recruitment status values:
Open recruitment status values:
Closed recruitment status values:
Values are color coded (as shown) in the search results.
Not all clinical trials in this database are accepting new participants. If you are looking for studies that are currently recruiting participants, will be recruiting in the future, or are about drugs that are available for expanded access, select Open Studies in the recruitment menu.
If you are interested in all trials, whether they are recruiting new participants or not, leave the menu with All Studies selected.
Trials may not be recruiting because they are full, completed, or halted for various reasons. In addition, some trials have very restrictive eligibility requirements and must seek participants by invitation only. To see these studies, Select Closed Studies in the recruitment menu.
Full list of all possible recruitment status values:
Open recruitment status values:
Recruiting,
Not yet recruiting, or
Available for expanded access.
Not yet recruiting, or
Available for expanded access.
Closed recruitment status values:
Active, not recruiting,
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Search Terms
Use this box to specify general search terms found anywhere in the trial record.
Multiple terms can be separated by an AND (all uppercase).
Examples:
type ii diabetes
veterans affairs medical center
heart attacks in older adults
nhlbi AND heart disease
Cisplatin AND safety study
Multiple terms can be separated by an AND (all uppercase).
Examples:
type ii diabetes
veterans affairs medical center
heart attacks in older adults
nhlbi AND heart disease
Cisplatin AND safety study
Help for Searching clinical trials
Help Topics:
Basic Search:
On the Basic Search page, enter a word or word(s) that you want to use to find studies.
These may include diseases, interventions, and/or locations.
Medical terms are often several words long, such as Percutaneous Coronary Intervention. To only find studies where the words are together as a phrase, put the term in quotes (e.g., "Percutaneous Coronary Intervention"). If you search for a multi-word term without quotes, studies with all words together as a phrase will appear higher in the results list than studies where the words are separated and spread throughout the document. For example, a search for Heart Attack will list a study about,
A search for "Heart Attack" would not find the second study. Synonyms are known for some terms and are used where possible. For example, a search for Heart Attack will also find occurrences of Myocardial Infarction.
Medical terms are often several words long, such as Percutaneous Coronary Intervention. To only find studies where the words are together as a phrase, put the term in quotes (e.g., "Percutaneous Coronary Intervention"). If you search for a multi-word term without quotes, studies with all words together as a phrase will appear higher in the results list than studies where the words are separated and spread throughout the document. For example, a search for Heart Attack will list a study about,
Use of a Pacemaker Following a Heart Attack.
higher than the study,
Heart Defects and Transient Ischemic Attacks
A search for "Heart Attack" would not find the second study. Synonyms are known for some terms and are used where possible. For example, a search for Heart Attack will also find occurrences of Myocardial Infarction.
Advanced Search:
Many searches are a single term and can be performed with a few words in the
search box. But, sometimes you need more control. Click on the Advanced Search tab
(if starting a new search) or Refine Search tab (if modifying an existing search)
to show additional search fields.
The additional search fields can be used to limit your search results. Note that it is not necessary to fill in all the fields, only those that are needed for your search. If you are finding too few studies, consider clearing a field and searching again.
Search Terms:
Recruitment:
Interventions:
Outcomes Measures:
Sponsor/Collaborators:
Sponsor (Lead):
Study IDs:
Country/State:
Location Terms:
Gender:
Age Group:
Phase:
Funded By:
Safety Issue:
First Received:
Last Updated:
The additional search fields can be used to limit your search results. Note that it is not necessary to fill in all the fields, only those that are needed for your search. If you are finding too few studies, consider clearing a field and searching again.
Search Terms:
Performs a general search in all sections of the study record, including title,
description, conditions, interventions, locations, etc. Terms in this field are
searched the same as Basic Search.
Recruitment:
Limits search results to studies that are open or closed. New volunteers may be
able to participate in open studies, but not closed studies.
Open recruitment status values:
Closed recruitment status values:
Values are color coded (as shown) in the search results.
Study Results:Open recruitment status values:
Recruiting,
Not yet recruiting, or
Available for expanded access.
Not yet recruiting, or
Available for expanded access.
Closed recruitment status values:
Active, not recruiting,
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Values are color coded (as shown) in the search results.
Limits search results based on whether the study has results or not:
Study Type:
All Studies,
Studies With Results, or
Studies Without Results
The inclusion of Study Results is a new feature of ClinicalTrials.gov.
Only a few studies have results available.Studies With Results, or
Studies Without Results
Limits search results to any of the following study types:
Conditions:
Interventional,
Observational, or
Expanded Access
Observational, or
Expanded Access
Performs a search on fields describing the diseases or conditions being studied.
Interventions:
Performs a search on fields listing the drugs or interventions being studied.
Outcomes Measures:
Performs a search on fields listing the outcome measures used to quantify study results.
Sponsor/Collaborators:
Performs a search on fields listing the sponsor and collaborators of a study.
When the Exact Match checkbox is checked, the sponsor/collaborator name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck in the sponsor/collaborator field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
When the Exact Match checkbox is checked, the sponsor/collaborator name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck in the sponsor/collaborator field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Sponsor (Lead):
Performs a search on the sponsor field of a study.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the "sponsor" is decided by the data provider.
When the Exact Match checkbox is checked, the lead sponsor name in the study must exactly match the lead sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the "sponsor" is decided by the data provider.
When the Exact Match checkbox is checked, the lead sponsor name in the study must exactly match the lead sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Study IDs:
Performs a search on fields listing ID numbers.
Country/State:
Trials are often conducted at many locations around the world.
Select up to three locations to find trials conducted in
specific countries. Some countries (currently limited to the
United States, Canada, and Australia), locations can be narrowed
further by selecting a state (e.g., United States, Alabama).
Location Terms:
Finds studies in specific locations such as a city (Los Angeles) or facility (Mayo Clinic).
Not all studies include this level of detail, but if they do, this will find them.
Gender:
Limits search results to those studies that accept female or male participants.
Age Group:
Limits search results to those studies that include at least one of the specified age
ranges. More than one age group can be selected.
Phase:
Limits search results to studies that are labeled with at least one of the specified
phases. More than one Phase can be selected.
Funded By:
Limits search results to studies that have at least one sponsor of the specified types.
More than one sponsor type can be selected.
Safety Issue:
Limits search results to studies that have at least one outcome measure designated as a safety issue.
First Received:
Limits search results to studies that were received by clinical trials within a
specified date range. The "From" or "To" field can be left blank.
Last Updated:
Limits search results to studies that were modified within a
specified date range. The "From" or "To" field can be left blank.
Refine Search:
Searches display a list of studies found (List Results tab). If you are not content with
the search results, click on the Refine Search tab at the top of the list to modify your
search.
Add terms to empty fields to search within your current result. You can also add terms to fields that contain terms. For best results, use an AND (all upper case) as a separator between terms in the same field.
For example:
When you are done making changes, click Search to display the new results.
Add terms to empty fields to search within your current result. You can also add terms to fields that contain terms. For best results, use an AND (all upper case) as a separator between terms in the same field.
For example:
heart attack
heart attack AND aspirin
heart attack AND aspirin AND older adults
heart attack AND aspirin AND older adults AND California
heart attack AND aspirin
heart attack AND aspirin AND older adults
heart attack AND aspirin AND older adults AND California
When you are done making changes, click Search to display the new results.
Search Expressions:
Use AND (all upper case) to find study records that contain all terms connected by AND.
For example:
Use OR (all upper case) to find study records that contain either term connected by OR.
For example:
Use NOT (all upper case) to find study records that do not contain the term following NOT.
For example:
Likewise, AND, OR, NOT, and parentheses can be used to create more complicated search expressions.
For example:
Note that the use of AND and OR as logical operators can be confusing.
An appropriate search for a list such as,
To search for AND as a word, instead of using it as an operator, put it in quotes.
Likewise, you can quote OR, NOT, and parentheses.
For example:
prostate cancer AND radiation
heart disease AND stroke AND California
heart disease AND stroke AND California
Use OR (all upper case) to find study records that contain either term connected by OR.
For example:
Aspirin OR ibuprofen
heart disease OR heart attack
heart disease OR heart attack
Use NOT (all upper case) to find study records that do not contain the term following NOT.
For example:
Immunodeficiency NOT AIDS
Likewise, AND, OR, NOT, and parentheses can be used to create more complicated search expressions.
For example:
prostate cancer AND NOT ( radiation OR homeopathic remedies )
( heart disease OR heart attack ) AND ( stroke OR clot )
( heart disease OR heart attack ) AND ( stroke OR clot )
Note that the use of AND and OR as logical operators can be confusing.
An appropriate search for a list such as,
Ear, Nose, and Throat Conditions
is the expression
( Ear OR Nose OR Throat ) AND Conditions
Fortunately, search will do a pretty good job of finding the right studies either way.To search for AND as a word, instead of using it as an operator, put it in quotes.
Likewise, you can quote OR, NOT, and parentheses.